DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specifi
| Agency | Dept. of the Army -- USAMRAA |
|---|---|
| Status | Posted |
| Opportunity number | HT942526ALSRPCOBA |
| Posted date | 05/04/2026 |
| Application deadline | Sep 30, 2026 12:00:00 AM EDT |
| Award ceiling | none |
| Award floor | none |
| Estimated total funding | 7,000,000 |
| Expected number of awards | 7 |
| Assistance Listing (CFDA) | 12.420 |
| Description | Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes . This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitori |
| Agency contact | help@eBRAP.org |
| Official listing | https://www.grants.gov/search-results-detail/362194 |